Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HTR6 | P50406 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14041863 | 0.85 | DPP4 (0.38) | DPP4DPP7HRH3ALDH1A1TSHR | |
| SCHEMBL4745990 | 0.85 | DPP4 (0.38) | DPP4DPP7HRH3ALDH1A1TSHR | |
| SCHEMBL26619663 | 0.83 | DPP4 (0.35) | DPP4DPP7HRH3 | |
| SCHEMBL24996299 | 0.82 | HRH3 (0.34) | HRH3 | |
| SCHEMBL4748656 | 0.82 | DPP4 (0.36) | DPP4DPP7HRH3ALDH1A1TSHR | |
| SCHEMBL14042280 | 0.82 | DPP4 (0.36) | DPP4DPP7HRH3ALDH1A1TSHR | |
| SCHEMBL2618405 | 0.79 | HRH3 (0.37) | HRH3ALDH1A1 | |
| SCHEMBL26632641 | 0.79 | HTR6 (0.31) | HTR6 | |
| SCHEMBL24317423 | 0.79 | DPP4 (0.33) | DPP4DPP7 | |
| SCHEMBL27010160 | 0.79 | FFAR4 (0.32) | HRH3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | IKZF1, IKZF3, IKZF2 | DPP4 2502/4885DPP7 3251/4885HRH3 4242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.